Evidence map›Paper›PMID 27746884›Full record

ArticleRare tumors2016

Erlotinib Induced Fatal Interstitial Lung Disease in a Patient with Metastatic Non-Small Cell Lung Cancer: Case Report and Review of Literature.

Ankit Mangla, Nikki Agarwal, Chou Carmel, Thomas Lad

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Rare tumors, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ankit ManglaDepartment of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA; Division of Hematology/Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA.
Nikki AgarwalDivision of Hematology/Oncology, John H. Stroger, Jr. Hospital of Cook County , Chicago, IL, USA.
Chou CarmelDivision of Hematology/Oncology, John H. Stroger, Jr. Hospital of Cook County , Chicago, IL, USA.
Thomas LadDivision of Hematology/Oncology, John H. Stroger, Jr. Hospital of Cook County , Chicago, IL, USA.
John H. Stroger, Jr. Hospital of Cook County · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erlotinib is one of the most widely used tyrosine kinase inhibitor targeting human epidermal growth factor receptor. Since its introduction, it has revolutionized the treatment of advanced non-small cell lung cancer. Skin rashes and diarrhea are the most often reported side effects of erlotinib however it is also associated with interstitial pneumonitis or interstitial lung disease, which often turns out to be fatal complication of using this medicine. Though reported scarcely in the western world, the association of interstitial lung disease with epidermal growth factor receptor has attracted a lot of attention in the recent times. Various researches working with murine models of bleomycin-induced pulmonary fibrosis have found a

Indexed as

Interstitial pneumonitisNon small cell lung cancerTyrosine kinase inhibitors

Identifiers

PMID27746884
PMCPMC5064300
OpenAlexW2528698262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.